Related Experiment Video
Updated: Jul 19, 2026
06:43
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Gastrointestinal stromal tumor (GIST)
1Department of Oncology, Helsinki University Central Hospital, Finland.
Summary
Gastrointestinal stromal tumors (GISTs) are rare mesenchymal tumors. Imatinib, a tyrosine kinase inhibitor, is effective for metastatic GIST, improving survival with moderate toxicity.
Area of Science:
- Oncology
- Gastroenterology
- Molecular Biology
Background:
- Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms of the GI tract.
- GISTs typically express KIT protein and harbor mutations in KIT or PDGFRA genes.
- Annual incidence in Caucasians is 10-15 cases per million.
Purpose of the Study:
- To review the characteristics, incidence, and treatment of GISTs.
- To discuss the role of tyrosine kinase inhibitors, particularly imatinib, in GIST management.
Main Methods:
- Literature review of GIST epidemiology and treatment modalities.
- Analysis of mutation profiles in GIST, including KIT and PDGFRA.
- Evaluation of imatinib efficacy and toxicity in metastatic GIST.
Main Results:
- ~80% of GISTs have KIT mutations, 5% have PDGFRA mutations.
- KIT mutations are common in exon 11; secondary mutations occur in imatinib-treated patients.
- 80-90% of metastatic GIST patients respond to imatinib (400-600 mg daily), improving survival.
Conclusions:
- Surgery is standard for localized GIST.
- Imatinib is the standard treatment for metastatic GIST, offering significant survival benefit.
- Imatinib's adjuvant use and other tyrosine kinase inhibitors are under investigation.
